BioSpace presents the NextGen Bio “Class of 2020,” a list of up-and-coming life sciences companies in North America that launched no earlier than mid-2018.
Companies continue to announce advancements in artificial intelligence programming as they harness the power of AI and machine learning to aid in drug discovery and development.
What do Microsoft, Aetna, Twitter, IBM, Ogilvy Consulting, Biogen and dozens of healthcare startups have in common? All appear in discussions about issues at the nexus of healthcare and technology in Icons.Health, a new video series produced by AbelsonTaylor.
Ad-ventures in Marketing XI
Artificial Intelligence, Business, Data Security, December 2018, Digiceuticals, Doctors, Gastroesophageal Reflux Disease (GERD), Healthcare Communications Agencies, Healthcare Physicians, Inflammatory Bowel Disease (IBD), Irritable Bowel Syndrome, Issue Archives, Joint Ventures, Marketing & Advertising, Partnerships, Patient Identification, Patients, Pharma, Pharmaceutical Marketing Ventures to Watch, Pharmacy Benefits, Rare Diseases, Rare Disorders, Sales Aids, Siri, Special Features, Start-Ups, TherapistsFor the 11th year, Med Ad News selected new Pharmaceutical Marketing Ventures to Watch that could change the way pharmaceutical products are marketed and sold.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
Medical startups must successfully mix entrepreneurial knowledge, a STEM-steeped education, and real-life experience to have the type of lasting impact they desire.
Boehringer Ingelheim Will Invest 11 Billion Euros in Research and Development in the Next Five Years to Accelerate the Discovery of Next Generation Medical Breakthroughs
Biomedical, Cardimetabolic, Central Nervous System, Drug Discovery, Immunology, Innovation, Irritable Bowel Syndrome, Oncology, Partnership, Partnerships, R&D, Respiratory, Start-Ups, Start-ups, Startups11 billion euro R&D programme through 2020, with 5 billion euro dedicated to pre-clinical R&D and 1.5 billion euro planned for cooperation with external partners New partnerships with the […]